Donepezil in Alzheimer's disease: What to expect after 3 years of treatment in a routine clinical setting
2007 (English)In: Dementia and Geriatric Cognitive Disorders, ISSN 1420-8008, E-ISSN 1421-9824, Vol. 23, no 3, 150-160 p.Article in journal (Refereed) Published
Wallin, Å.K., Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, Department of Clinical Sciences, Malmö, Lund University, Malmö University Hospital, SE-205 02 Malmö, Sweden.
Karolinska Institutet, Department of Neurotec, Karolinska University Hospital, Huddinge, Stockholm, Sweden.
Section of Geriatric Medicine, Department of Community Medicine and Rehabilitation, Umeå University, Umeå, Sweden, Department of Community Medicine and Rehabilitation, Umeå University, Umeå, Sweden.
Båtsman, S., Department of Primary Care, Kalix Vårdcentral, Kalix, Sweden.
Background/Aims: Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer's disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated. Methods: The Swedish Alzheimer Treatment Study (SATS) is a descriptive, prospective, longitudinal, multicentre study. Four hundred and thirty-five outpatients with the clinical diagnosis of Alzheimer's disease, received treatment with donepezil. Patients were assessed with Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), global rating (CIBIC) and Instrumental Activities of Daily Living (IADL) at baseline and every 6 months for a total period of 3 years. Results: The mean MMSE change from baseline was positive for more than 6 months and in subgroups of patients for 12 months. After 3 years of treatment the mean change from baseline in MMSE-score was 3.8 points (95% CI, 3.0-4.7) and the ADAS-cog rise was 8.2 points (95% CI, 6.4-10.1). This is better than expected in untreated historical cohorts, and better than the ADAS-cog rise calculated by the Stern equation (15.6 points, 95% CI, 14.5-16.6). After 3 years with 38% of the patients remaining, 30% of the them were unchanged or improved in the global assessment. Conclusion: Three-year donepezil treatment showed a positive global and cognitive outcome in the routine clinical setting. Copyright © 2007 S. Karger AG.
Place, publisher, year, edition, pages
2007. Vol. 23, no 3, 150-160 p.
Alzheimer's disease, Cholinesterase inhibitor, Donepezil
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-50011DOI: 10.1159/000098052OAI: oai:DiVA.org:liu-50011DiVA: diva2:270907